In support of our hypothesis, ibrutinib has been shown to inhibit the PI3K/Akt pathway, including indirect downregulation of PI3K-p110a28–30and reduced PIK3CA activation has been related to increased susceptibility to AF and cardiac conduction deterioration31,32. Here, AKT1 is linked to atrial fibrillation.